Voyager Acquisition Corp. II
Blank check SPAC shell seeking $220M IPO to merge with an unnamed tech, fintech, or healthcare target.
On the record
Checkpoint: IPO pricing and listing, still unpriced as of the last check
The call
VAII is an unpriced, unfunded shell with a 24-month deadline to find and close a deal, and its sponsor's last SPAC saw 99.67% of shareholders redeem out at the vote.
Voyager Acquisition Corp. II is an empty shell company that has raised $220 million and has 24 months to find a real operating business to purchase and merge with, or it must return the money to investors and shut down. The company's sponsor family ran a similar blank-check vehicle before (VACH, which became VERAXA), and when that one finally announced a target, nearly 100 percent of investors pulled their money out and asked for refunds, which is a bad sign for this sponsor's ability to pick winning companies. The one thing that matters most is whether this sponsor can find and close a good acquisition deal before the deadline expires, because the track record from their last vehicle suggests investors have little confidence in their deal-picking skills.
Why
01
AI pressure: None apparent. There is no product, customer base, or revenue line for AI to disrupt; the shell itself does nothing operational yet. Could AI do the core job? Yes, likely.
02
Bigger players: None apparent. With no target named, there is no market position for a big company to attack; the risk is sourcing a deal at all, not competing in one. Could a giant copy it? Yes, easily.
03
What protects it. None identified; trust account cash and redemption rights protect investor capital but nothing protects VAII's own economics.
What would change this call
VAII prices and lists its $220M IPO on Nasdaq or NYSE within 2026. Shows the shell actually raised capital and started its 24-month combination clock.
VAII files an 8-K naming a definitive merger target in tech, fintech, or healthcare. Shifts evaluation from the empty shell to the real target company's business quality.
Shareholder redemption rate at VAII's eventual deal-approval vote, compared to VACH's ~99.67%. Indicates whether investors trust this sponsor's deal-picking more than they did last time.
VAII files an 8-K naming a definitive merger target in tech, fintech, or healthcare. Shifts evaluation from the empty shell to the real target company's business quality.
Shareholder redemption rate at VAII's eventual deal-approval vote, compared to VACH's ~99.67%. Indicates whether investors trust this sponsor's deal-picking more than they did last time.
Key numbers
- $220M target IPO, 22M units at $10 each
- $0 revenue, $0 net income, trailing twelve months
- Implied market cap ~$275M at $10 unit price
Named risks
- No named merger target as of July 29, 2026, with a 24 month clock starting only once IPO closes.
- Sponsor's prior SPAC VACH suffered 99.67% shareholder redemption at deal approval, March 2026.
- Crowded 2026 SPAC vintage of 6+ peers competing for the same thin pool of quality targets.
- Mandatory trust liquidation if no combination completes within 24 months of IPO.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Viking Acquisition Corp. II | contesting | priced $200M IPO on 2026-07-01, same tech/fintech/healthcare target pool |
| Pelican Acquisition II Corp | contesting | closed ~$86.25M IPO on 2026-07-27, competing for same scarce targets |
| Willow Lane Acquisition Corp. II, Berto II, Breeze II, Collective II | contesting | six or more identically structured $10/unit SPACs priced in H1 2026 wave |
Questions people ask
- Is Voyager Acquisition Corp. II a real operating company?
- No. VAII is a blank check Cayman Islands SPAC shell with $0 revenue and $0 net income as of July 11, 2026, formed only to pursue a future merger in tech, fintech, or healthcare. It filed its Form S-1 on March 13, 2026, and had not priced its IPO as of July 29, 2026.
- Has Voyager Acquisition Corp. II found a merger target yet?
- No target had been named as of July 29, 2026. VAII's S-1, filed March 13, 2026, seeks $220 million via 22 million units at $10 each, but the company must still identify, negotiate, and close a deal within a 24-month deadline after IPO or face mandatory trust liquidation.
- Who runs Voyager Acquisition Corp. II?
- Adeel Rouf is President and CEO, managing the sponsor entity Voyager Acquisition Sponsor Holdco II LLC. Warren Hosseinion, MD, chairs the board and also chairs Cardio Diagnostics and co-founded Apollo Medical Holdings. Cantor Fitzgerald & Co. is the lead underwriter, per filings as of March 2026.
- Is investing in Voyager Acquisition Corp. II risky?
- Yes. The sponsor's prior SPAC, Voyager Acquisition Corp (VACH), saw about 99.67% shareholder redemption when its VERAXA Biotech merger was approved on March 12 to 13, 2026, signaling weak investor confidence in this sponsor team's deal outcomes ahead of the deal closing around June 8, 2026.
- When will Voyager Acquisition Corp. II IPO?
- As of July 29, 2026, VAII had filed its S-1 (March 13, 2026) targeting a $220 million IPO of 22 million units at $10 each, but had not yet priced or begun trading. The exact IPO date remained unset per stockanalysis.com data dated July 11, 2026.
- Could AI replace Voyager Acquisition Corp. II?
- There is nothing to replace: VAII has no product, customers, or operating business, only a legal shell and trust account. AI could assist sponsor-side deal sourcing or legal drafting, but this is a capital markets vehicle, not a company with an AI-exposable workflow, as of July 2026.
Timeline
- 2026-07-29VAII IPO still unpriced; no merger target named, per stockanalysis.com
- 2026-07-27Comparable peer Pelican Acquisition II Corp closes ~$86.25M IPO
- 2026-07-01Comparable peer Viking Acquisition Corp. II prices $200M IPO
- 2026-06-08Sister entity VACH's merger with VERAXA Biotech AG closes
- 2026-03-13VAII files Form S-1 for $220M IPO of 22M units at $10 each
- 2026-03-12VACH shareholders approve VERAXA merger; ~99.67% redeem shares
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- SPAC Voyager Acquisition II files for a $220 million IPO, targeting tech, fintech, and healthcare (2026-03-12)
- Voyager Acquisition II (2026-03-12)
- Underwriting Agreement between Voyager Acquisition Corp. II
- Voyager Acquisition Corp. II Insider Letter Agreement Relating
- Team
- Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG (2026-03-13)
- Viking Acquisition Corp. II Announces Pricing of $200,000,000 Initial Public Offering (2026-07-01)
- Pelican Acquisition II Corporation Announces Closing of (2026-07-29)
- 200 Most Recent IPOs (2026-07-23)
- Voyager Acquisition Corp. II (VAII) Stock Price & Overview (2026-07-11)
- 110+ Spac Statistics (2026-02-12)
- SPACs Flame Out in SPACtacular Fashion. Was It Inevitable? (2023-10-22)